title: The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy.
abstract: To evaluate galectin-1, -3 and -7 serum levels as diagnostic and/or prognostic markers for head and neck squamous cell carcinomas (HNSCCs). ELISA was employed to test sera from 102 patients with HNSCCs and from 38 healthy control volunteers for galectin-1, -3 and -7 serum levels. Serum galectin levels were assayed by ELISA and the levels of galectin expression in HNSCCs were determined by means of immunohistochemistry. HNSCCs display significant immunohistochemical amounts of galectin-7, but this galectin cannot be detected in the blood of HNSCC patients. Galectin-3 levels differ significantly (p=0.03) in healthy volunteers and HNSCC patients. Using a threshold value of 4.3 ng/ml, galectin-3 serum level enabled a significant level of discrimination (p=0.03) to be established between the cancer patients and the healthy volunteers, with 90% level of specificity and 36% level of sensitivity. The discrimination was even better when using a threshold value of 13.5 ng/ml for galectin-1 (p=0.001), with 100% level of specificity and 22% level of sensitivity. A subgroup of stage IV HNSCC patients displayed significantly reduced levels of circulating galectin-1 (p=0.003) and galectin-3 (p=0.001) after treatment as opposed to before. Galectin-3 concentrations in sera from the patients with a metastatic disease were significantly (p=0.01) higher than in sera from the patients with localized tumors. The determination of circulating levels of galectin-1 and -3 could be used to monitor the progression of their disease or their response to therapy.
authors.affiliation: Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons-Hainaut, Mons, Belgium. sven.saussez@umh.ac.be
authors.forename: Sven
authors.initials: S
authors.lastname: Saussez
authors.forename: Francois
authors.initials: F
authors.lastname: Lorfevre
authors.forename: Thomas
authors.initials: T
authors.lastname: Lequeux
authors.forename: Guy
authors.initials: G
authors.lastname: Laurent
authors.forename: Gilbert
authors.initials: G
authors.lastname: Chantrain
authors.forename: Francoise
authors.initials: F
authors.lastname: Vertongen
authors.forename: Gérard
authors.initials: G
authors.lastname: Toubeau
authors.forename: Christine
authors.initials: C
authors.lastname: Decaestecker
authors.forename: Robert
authors.initials: R
authors.lastname: Kiss
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis*; D004797:Enzyme-Linked Immunosorbent Assay; D005240:Feasibility Studies; D005260:Female; D037483:Galectin 1 / Q000097:blood*; D037502:Galectin 3 / Q000097:blood*; D037161:Galectins / Q000097:blood; D006258:Head and Neck Neoplasms / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D037483:Galectin 1; D037502:Galectin 3; D037161:Galectins; C092525:LGALS7 protein, human